I'm heading to #NeurIPS24 in Vancouver next week. Ping me if you'd like to meet up for a ☕ (preferably a ristretto for me...) and discuss how AI is transforming biology, or delve into more hardcore ML topics!
🎉 Excited to share that we've just hit a $76M funding milestone for Bioptimus, with a fresh $41M round to build the first multiscale foundation model of biology: www.bioptimus.com/news/bioptim...
If you're curious of what is "behind a term sheet", don't miss this account by the Cathay innovation team who led our recent series A at Bioptimus
medium.com/cathay-innov...
I've been eagerly awaiting this book for years! At last, a standalone and meticulous exposition of the current mathematical principles of machine learning, adorned with beautiful proofs. Well done and thank you,
@bachfrancis.bsky.social . Discover more here: francisbach.com/my-book-is-o...
Honored to join @AcadTechnolog (National Academy of Technologies of France)! Grateful to my teachers, students, and collaborators over the years. I’ll strive to advance thoughtful, inclusive progress in tech and help society understand innovations like AI.
Ready to launch the #hackathon on #glioblastoma to kick off the AI action summit in Paris: 130 experts gather in Paris to explore the biology of this deadly brain cancer with novel data and #AI tools! See you in 48h for the results
www.owkin.com/connect/glio...
Catch my talk at the CZI virtual cells AI workshop at #NeurIPS24 to gain insight into how we develop the foundational elements of AI for biology at @Bioptimus and how we apply them at @Owkin to add value throughout the entire drug development process:
Back in SF for #JPM25! Eager to explore and discuss the cutting-edge advancements of AI in healthcare.
🧘♀️And to beat jet lag next Monday, nothing better than a free charity fitness class hosted by @owkin.bsky.social at the Equinox Sports Club in San Francisco www.owkin.com/connect/fitn...
We’re excited to announce the first patient has been dosed in our Phase 1 clinical trial of OKN4395, a first-in-class EP2/EP4/DP1 triple inhibitor for solid tumors.
Learn more in STAT’s latest interview with Andrew Pierce, Owkin’s SVP Discovery & Development: www.statnews.com/2025/01/30/o...
